A protocol for the retina surgeon's safe initial intravitreal injections

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1279-1285

  Frenkel, Ronald E P ^a,b   Haji, Shamim A ^a,b   La, Melvin ^a   Frenkel, Max P C ^a   Reyes, Angela ^a  

^a Eye Research Foundation   (United States)

^b East Florida Eye Institute   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Endophthalmitis; Intraocular disease; Intravitreal injection; Pegaptanib; Post injection complications; Ranibizumab

Indexed keywords

AGENTS ACTING ON THE EYE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

ABRASION; AGED; ARTERY THROMBOSIS; CLINICAL PROTOCOL; CORNEA EDEMA; CORNEAL ABRASION; ENDOPHTHALMITIS; EYELID SWELLING; FEMALE; GLAUCOMA; HUMAN; LIGHT PERCEPTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT SAFETY; PERCEPTION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SIDE EFFECT; SURGEON; SWELLING; TRAUMATIC CATARACT; VISION; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 78650707766     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S12846     Document Type: Review

References (21)

1. Centers for Medicare and Medicaid Services. Medicare Utilization for Part B. [cited 2008 Aug 16]. Available from: http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/04_MedicareUtilizationforPartB.asp. Accessed 2010 Oct 2.
2. Eye Diseases Prevalence Research Group. Prevalence of age related macular degeneration in the United States. Arch of Ophthalmol. 2004;122:564-572.
3. Gopal L, Sharma T, Shanmugam M, et al. Surgery for stage 5 retinopathy of prematurity: the learning curve and evolving technique. Indian J Ophthalmol. 2000;48(2):101-106.
4. Lee J, Hou C, Yang M, Kuo JZ, Lin K. A different approach to assess resident phacoemulsification learning curve: analysis of both completion and complication rates. Eye. 2009;23(3):683-687.
5. Al-Swailem SA, Wagoner MD. Complications and visual outcome of LASIK performed by anterior segment fellows vs experienced faculty supervisors. Am J Ophthalmol. 2006;141(1):13-23.
6. Yildirim R, Devranoglu K, Ozdamar A, Aras C, Ozkiris A, Ozkan S. Flap complications in our learning curve of laser in situ keratomileusis using the Hansatome microkeratome. Eur J Ophthalmol. 2001;11(4): 328-332.
7. Randleman JB, Wolfe JD, Woodward M, Lynn MJ, Cherwek DH, Srivastava SK. The resident surgeon phacoemulsification learning curve. Arch Ophthalmol. 2007;125(9):1215-1219.
8. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology. 2003; 110(5):979-986.
9. D'Amico DJ, Masonson HN, Patel M, et al; for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992-1001.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double- masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol. 2008; 145(2):239-248.
11. Rossi JV, Verma D, Fujii GY, et al. Virtual vitreoretinal surgical simulator as a training tool. Retina. 2004;24(2):231-236.
12. Csaky DK. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology. 2003;10(5):879-881.
13. Schmidt-Erfurth UM, Pruente C. Management of neovascular agerelated macular degeneration. Prog Retin Eye Res. 2007;26(4): 437-451.
14. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2010; DOI: s10792-008-9243-1. Accessed 2010 Oct 2.
15. Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143(6):1034-1035.
16. Rosenfeld PJ, Brown DM, Heier JS, et al; and the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
17. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR; for the VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
18. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5):S3-S19.
19. Apt L, Isenberg S, Yoshimori R, Paez J. Chemical preparation of the eye in ophthalmic surgery III: effect of povidone-iodine on the conjunctiva. Arch Ophthalmol. 1984;102:728-729.
20. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698.
21. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography- measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2010;30(2):203-211.